GlassScriptPhysician profile
Muthukrishnan Vasantha-Kumar
NPI 1982671210
$409.09
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $81.97 · 2021: $75.98 · 2022: $91.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.58 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.04 | 2019 | |
| Horizon Therapeutics Plc | $33.26 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.40 | 2019-2022 | |
| Ucb, INC. | $24.48 | 2021 | |
| Glaxosmithkline, LLC. | $21.52 | 2021 | |
| Acadia Pharmaceuticals INC | $20.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.66 | 2019 | |
| Sanofi Pasteur INC. | $17.83 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.14 | 2022 | |
| Pfizer INC. | $12.85 | 2020 | |
| Amarin Pharma, INC. | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muthukrishnan Vasantha-Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.